Contact Person

Dr. Barbara Tshisuaka

Managing Editor

Phone: +49 (0)711 - 2 29 87 33
Fax: +49 (0)711 - 2 29 87 65
send an Email


Survey of management of solitary thyroid nodules in Germany

Journal: Nuklearmedizin
ISSN: 0029-5566
Issue: 2008 (Vol. 47): Issue 3 2008 (87-138)
Pages: 87-96

Survey of management of solitary thyroid nodules in Germany

M. Dietlein1, K. Wegscheider2, R. Vaupel3, M. Schmidt1, H. Schicha1
1Department of Nuclear Medicine, University of Cologne, 2Institute of Statistics and Econo metrics, University Hamburg, 3Sanofi-Aventis Deutschland GmbH, Berlin, Germany


Questionnaire, Primary Care, radioiodine therapy, calcitonin, thyroid nodule, iodine, levo thyroxine


Aim: To compare the opinions of practitioners in primary care with those of thyroid specialists in Germany on the management of solitary thyroid nodules (Papillon 2005). Methods: Questionnaires were filled in by 2,191 practitioners and 297 thyroid specialists between June 1 and September 30, 2005. The test cases and their modifications described a solitary thyroid nodule of 2–3 cm with different levels of thyroid function and a hypoechogenic nodule of 1 cm in diameter. Results: TSH determination and sonography were found to be standard procedures, followed by scintigraphy (selected by 84.7% of practitioners and 95.1% of specialists, p < 0.001) and fine needle aspiration cytology (54.5% of practitioners, 57.4% of specialists). For a hypoechogenic nodule calcitonin determination was advocated by 54.0% of endocrinologists and by 32.2% of nuclear medicine physicians (p < 0.001). A euthyroid solitary thyroid nodule would be treated medically by 77.8% of practitioners and by 85.7% of specialists, the combination of levothyroxine and iodine being clearly preferred (60.9% of practitioners and 67.1% of specialists). For a hyperfunctioning nodule the preference of radioiodine therapy was significantly higher in the specialist group (88.8%) than among the practitioners (52.2%). Conclusions: The main differences of opinion between practitioners and specialists focused on calcitonin screening and referral to radioiodine therapy.

You may also be interested in...


M. Dietlein1, K. Wegscheider2, R. Vaupel3, M. Schmidt1, H. Schicha1

Nuklearmedizin 2007 46 3: 65-75


M. Dietlein1, H. Wieler2, M. Schmidt1, R. Schwab3, P. E. Goretzki4, H. Schicha1

Nuklearmedizin 2008 47 2: 65-72

M. Dietlein, C. Kobe, M. Schmidt, H. Schich

Nuklearmedizin 2005 44 5: 213-224